« Return to News | Drug Sponsors

Analysts eye Pfizer break-up

Monday, May 2, 2011 01:22 PM

Analysts have been eyeing the prospect of a Pfizer break-up; they figure Pfizer would be worth $180 billion in pieces, according to Fierce Pharma.

Fierce notes some of Forbes quotes for potential prices of Pfizer units--animal health, $16 billion; nutritionals, $8 billion; and consumer health, $6 billion; established products business, which sells off-patent drugs, $40 billion.  The rest of core business would be estimated at $110 billion.

The divestment is creating lots of buzz, even though the strategic review of Pfizer assets will likely continue for the rest of this year.  CEO Ian Read seems to be leaning toward some sell-offs, reports Fierce Pharma. "My sense is he's already made up his mind," says Goldman Sachs analyst Jami Rubin, who's been calling for a Pfizer break-up for years.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.